Articles Tagged With: Pharmacology
-
Twice-Yearly Subcutaneous Lenacapavir Injection Prevents HIV Infection
Subcutaneous injection of lenacapavir every 26 weeks had 100% efficacy in preventing human immunodeficiency virus (HIV) infection in a high-risk population.
-
Inavolisib Tablets (Itovebi)
The U.S. Food and Drug Administration (FDA) has approved inavolisib, a phosphatidylinositol 3-kinase (PI3K) inhibitor, for the treatment of advanced hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a PIK3CA mutation. Inavolisib was granted a priority review and Breakthrough Therapy Designation.
-
Long-Term Proton Pump Inhibitor Use and the Risk of Colorectal Cancer
A large retrospective cohort study demonstrated that long-term use of proton pump inhibitors is associated with an increased risk of developing colorectal adenocarcinoma.
-
Xanomeline and Trospium Chloride Capsules (Cobenfy)
The U.S. Food and Drug Administration has approved the first-in-class muscarinic agonist and antagonists for the treatment of schizophrenia in adults. This is the first antipsychotic drug approved in decades and is unique in that it targets cholinergic receptors — unlike traditional agents, which target dopamine receptors.
-
Lebrikizumab-lbkz Injection (Ebglyss)
The U.S. Food and Drug Administration has approved a humanized monoclonal antibody that targets interleukin-13 for the treatment of moderate-to-severe atopic dermatitis.
-
Epinephrine Nasal Spray (Neffy)
The U.S. Food and Drug Administration has approved epinephrine nasal spray for the emergency treatment of allergic reactions, including anaphylaxis. It was granted a fast-track designation and will be distributed by ARS Pharmaceuticals as Neffy.
-
Sofpironium Topical Gel (Sofdra)
The U.S. Food and Drug Administration has approved a second topical anticholinergic product for the treatment of hyperhidrosis.
-
Chlorthalidone vs. Hydrochlorothiazide for Hypertension
A subgroup analysis of those with prior myocardial infarction or ischemic stroke in the Diuretic Comparison Project for the treatment of hypertension has found that this higher-risk group experiences fewer major adverse cardiovascular events while taking chlorthalidone compared to hydrochlorothiazide, but at the expense of more hypokalemia.
-
Donanemab-azbt (Kisunla)
The U.S. Food and Drug Administration has approved the third anti-amyloid beta monoclonal antibody for the treatment of Alzheimer’s disease, following aducanumab and lecanemab.
-
Elafibranor Tablets (Iqirvo)
The U.S. Food and Drug Administration has approved an oral dual peroxisome proliferator-activated alpha and delta receptor agonist for the treatment of primary biliary cholangitis, formerly known as primary biliary cirrhosis. Elafibranor was granted an accelerated approval and an orphan designation.